At the time of writing, Nektar Therapeutics [NKTR] stock is trading at $1.02, up 2.00%. An important factor to consider is whether the stock is rising or falling in short-term value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on December 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6.50. Previously, Piper Sandler started tracking the stock with Overweight rating on November 04, 2024, and set its price target to $7. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $2 on June 28, 2024. TD Cowen upgraded its rating to Outperform for this stock on November 09, 2023. In a note dated May 10, 2023, Jefferies upgraded an Hold rating on this stock and revised its target price from $1.50 to $1.
For the past year, the stock price of Nektar Therapeutics fluctuated between $0.46 and $1.93. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.02 at the most recent close of the market. An investor can expect a potential return of 1542.16% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
According to Nektar Therapeutics [NASDAQ:NKTR], the company’s sales were 93.14M for trailing twelve months, which represents an -0.08% plunge. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0007 points at the first support level, and at 0.9813 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0347, and for the 2nd resistance point, it is at 1.0493.
Ratios To Look Out For
It is important to note that Nektar Therapeutics [NASDAQ:NKTR] has a current ratio of 4.24. On the other hand, the Quick Ratio is 4.24, and the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 2.02, the price to book ratio is 3.85.
Transactions by insiders
Recent insider trading involved ROBIN HOWARD W, Officer, that happened on Dec 17 ’24 when 46995.0 shares were purchased. Chief R&D Officer, Zalevsky Jonathan completed a deal on Nov 19 ’24 to sell 7785.0 shares. Meanwhile, Chief Legal Officer Wilson Mark Andrew sold 6407.0 shares on Nov 19 ’24.
